gamma-Amino-beta-hydroxybutyric acid as add-on therapy in adult patients with severe focal epilepsy.
Total seizure frequency was evaluated among adult patients with severe partial epilepsy refractory to medical treatment. Clinical status was assessed before, and after a synthetic analog of gamma-amino-beta-hydroxybutyric acid (GABOB) was used as add-on therapy. Twenty-five patients with temporal and frontal lobe epilepsy were included in the trial. They received GABOB 250 mg twice daily during a 26-week period. Concentrations of concomitant antiepileptic medication were not modified. Twenty-five percent of the patients showed a 50% reduction of the total seizure frequency. There were no serious adverse effects related to medication.